A vaccine for the deadly Meningococcus B has been shown to have 79% effectiveness in patients under the age of 18. Meningococcus group B is the most common meningococcal infection and until now no studies had demonstrated the effectiveness of the 4CMenB (Bexsero) vaccine over time in the real-world, using a comparison of vaccination rates [ ]
The post Meningococcus B vaccine shows 79% effectiveness appeared first on Health Europa.
Thursday 28 January 2021
⁞
Sources